Tuesday, October 4, 2022


Biotechnology News Magazine

Amador Bioscience Appoints New Chief Technology Officer

Dr. Meina Liang has joined the company as Chief Technology Officer.

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Amador Bioscience, a global translational sciences and clinical pharmacology CRO, announced today that Dr. Meina Liang has joined the company as Chief Technology Officer. Dr. Liang will report to Amador CEO and Chairman of the Board Dr. Bing Wang Ph.D. As Chief Technology Officer, Dr. Liang will lead the strategy to establish cutting-edge bioanalysis technologies and capabilities, enhancing Amador’s global-standard services to biopharmaceutical companies.

“We could not be more excited to welcome Dr. Liang to Amador,” says Dr. Wang. “With 30 years of industry experience, she is a world-renowned expert in the development of small molecules and biologics. Dr. Liang is an outstanding leader with great communication skills, experienced in leading a global bioanalytical organization. I am confident that under her leadership, Amador Bioscience can further expand our global laboratory services, while keeping Amador’s pledge to provide efficient and high-quality work to our biopharmaceutical clients.”

Dr. Liang comes to Amador with extensive experience in pharmaceutical development and in global regulatory submissions. Most recently, Dr. Liang was Executive Director and Global Head of Integrated Bioanalysis at AstraZeneca, leading a centralized GxP function supporting AstraZeneca portfolio from discovery to post marketing across therapeutic areas and drug modalities. She played key roles in the successful regulatory submissions and market approvals of multiple drug entities. Prior to AstraZeneca, she held multiple scientist and leadership positions with increasing responsibilities at Berlex Bioscience/Schering AG, Abgenix/Amgen, and Medimmune. She is an inventor for 10+ patents, an author for 60+ peer-reviewed articles, and an invited speaker at numerous international conferences. Dr. Liang has participated in cross-industry working groups to generate guidance papers. She received her B.S. in Pharmacy from Beijing University in China and her Ph.D in Pharmacology from University of North Carolina at Chapel Hill

Amador is building an industry-leading CRO with advanced technologies and comprehensive capabilities. I’m excited to be a part of it,” says Dr Liang. “My entire career has been focusing on applying cutting edge technologies to solve complex problems in pharmaceutical development, and that’s what Amador does every day. The pharmaceutical field is fast expanding into new drug modalities that requires innovation and new technologies. The team at Amador is laser-focused on providing innovative solutions to support novel drug development. As I join Amador, I know that I’m joining a team of talented scientists dedicated to innovation in the industry, and I’m very excited to see what we can do together.”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine